Skip to main content
. 2019 Apr 2;11(4):770. doi: 10.3390/nu11040770

Figure 2.

Figure 2

ARE-luciferase activity, HO-1 protein expression, and cell viability in p53+/+ and p53−/− HCT116 cells in the presence of luteolin and/or oxaliplatin. Cells were seeded in a 6-well plate, a 100-mm dish, or a 96-well plate and treated with 5 or 25 μM luteolin in the absence or presence of 1 μM oxaliplatin at for 24 h, followed by measurement of the ARE activity, Western blot analysis for HO-1 expressions or cell viability assay. (A) Relative ARE-luciferase activity. Data are expressed as mean ± SD of three independent experiments. A significant difference compared to the control group at p < 0.05 was indicated by an asterisk. (B) Representative Western blots of protein expression changes of HO-1. (C) Relative cell viability assayed using a CCK-8 kit. Data are expressed as mean ± SD of three independent experiments. A significant difference compared among the groups at p < 0.05 was indicated by different alphabetical letters.